Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: Toxicity or benefit?

Japanese Journal of Clinical Oncology

Volumn 37, Issue 3, 2007, Pages 224-229

  Hofmann, Maja A ^a   Sterry, Wolfram ^a   Trefzer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemoimmunotherapy; Metastatic melanoma; Survival; Toxicity

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; VINDESINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DERMATOLOGY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPOKALEMIA; INFECTION; LETHARGY; LEUKOPENIA; MALE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE HYPOTONIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; WARD;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME; VINDESINE;

EID: 34447644274     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym009     Document Type: Article

References (33)

1. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised trials. Lancet Oncol 2003;4:748-59.
2. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12:806-11.
3. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH. Phase III clinical trial of cisplatin, darcarbazine and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999;17:1884-90.
4. Buzaid AC, Legha S, Winn R, Belt R, Pollock T, Wiseman C, et al. Cisplatin, vinblastine, and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma: Preliminary results of a phase II Cancer Community Oncology Program (CCOP) trial. Proc Am Soc Clin Oncol 1993;12:389.
5. Saxman SB, Meyers ML, Chapman PB, Destro AN, Panageas KS, Begg CB, et al. A phase II multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma. Proc Am Soc Clin Oncol 1999;18:536.
6. Falkson CI, Ibrahim J, Kirkwood J, Coates AS, Atkins MB, Blum R. Phase III trial of dacarbazine versus dacarbazine with interferon 2b versus dacarbazine with tamoxifen versus dacarbazine with interferon 2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study (E3690). J Clin Oncol 1998;16:1743-51.
7. Thatcher N, Dazzi H, Johnson RJ, Russell S, Ghosh AK, Moore M, et al. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. Br J Cancer 1989;5:770-74.
8. Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 1990;10:1650-56.
9. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin KA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
10. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
11. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, et al. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 1993;72:607-14.
12. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993, 11:1969-77.
13. Garbe C, Kreuser ED, Zouboulis CC, Stadler R, Orfanos CE. Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Sem Oncol 1992;(Suppl 4):63-9.
14. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-43.
15. Legha SS, Buzaid AC. Role of recombinant Il-2 in combination with interferon-alpha and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993;(Suppl 9):27-32.
16. Atkins MB, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, et al. Multiinstutional phase II trial of intensive combination chemotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-60.
17. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, et al. Sequential chemoimmuntherapy with cisplatin, interleukin-2 and interferon alfa 2a for metastatic melanoma. J Clin Oncol 1993;11:2173-80.
18. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997;(Suppl 24):S39-43.
19. Proebstle TM, Fuchs T, Scheibenbogen C, Sterry W, Keilholz U. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res 1998;8:557-63.
20. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:1600-7.
21. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996, 7:827-35.
22. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-9.
23. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
24. Trefzer U, Hofmann M, Sterry W, Asadullah K. Cytokine and anticytokine therapy in dermatology. Expert Opin Biol Ther 2003;3:733-43.
25. McDermott Mier JW, Lawrence DP, van den Brink MRM, Clancy MA, Rubin KM, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2000;6:2201-8.
26. Di Lauro V, Scalone S, La Mura N, Zanetti M, Nigri P, Freschi A, et al. Combined chemoimmunotherapy of metastatic melanoma: A single institution experience. Melanoma Res 2005;15:209-12.
27. Ahmann DL, Creagan ET, Hahn RG. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989;63:224-7.
28. Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, et al. IFNalpha/Il-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-88
29. Johnston SR, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, et al. Randomized phase II trial of BCDT with or without interferon alpha and interleukin-2 in patients with metastatic melanoma. Br J Cancer 1998;77:1280-6.
30. Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, et al. A phase II study of 'decrescendo' interleukin-2 plus interferon alpha 2a in patients with progressive metastatic melanoma after chemotherapy. Cancer 2000;88:1703-9.
31. Thomson DB, Adena M, McLeod GR, Hersey P, Gill PG, Coates AS, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanom: Results of a multi-institutional Australian trial. Melanoma Res 1993;3:133-8.
32. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999, 17:968-75.
33. El-Maraghi R, Verma S, Charette M, Markman B, Quirt I. A meta-analysis of biochemotherapy (BCT) for the treatment of metastatic malignant melanoma (MM). Proc Am Soc Clin Oncol 2004;22:717.